Skip to main content
. Author manuscript; available in PMC: 2018 Jul 5.
Published in final edited form as: Vaccine. 2017 Jun 10;35(31):3817–3822. doi: 10.1016/j.vaccine.2017.06.002

Table 4.

Enterovirus 71 and coxsackievirus 16 antibody GMT at 0, 3 and 6 months of age for the 2 initial antibody level categories. 95% confidence intervals are given in parentheses and sample size is in brackets.

Initial antibody category Mo 0 Mo 3 Mo 6
EV71(N) ≥1:48 115.2 (96.1, 138.1) [71] 13.3 (10.5, 16.9) [63] 4.7 (3.9, 5.8) [22]
Proportion 100% 11.5% 4.1%
<1:48 8.9 (7.9, 10.1) [156] 4.4 (4.2,4.6) [138] 4.4 (3.7, 5.3) [47]
Proportion 100% 49.4% 49.4%
CoxA16(N) ≥1:48 83.9 (67.2,104.9) [55] 14.3 (10.9,18.9) [50] 4.5 (3.8, 5.4) [15]
Proportion 100% 17.0% 5.4%
<1:48 9.7 (8.6, 10.8) [172] 4.5 (4.3,4.8) [151] 4.5 (3.6,5.7) [53]
Proportion 100% 46.4% 46.4%

The initial antibody level (Mo 0) was taken as 100% and the proportion for EV71 and CoxA16 antibodies were shown for Mo 3 and Mo 6.